Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
1997
DOI: 10.1172/jci119380
|View full text |Cite
|
Sign up to set email alerts
|

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

14
153
0
3

Year Published

1997
1997
2017
2017

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 299 publications
(171 citation statements)
references
References 31 publications
14
153
0
3
Order By: Relevance
“…16 Cidofovir is the most potent inhibitor of KSHV productive infection. 18 Clinical and viral evidence presented here demonstrates that 4 months of therapy with cidofovir had no effect on KSHV-related MCD. Other mechanisms beyond productive viral replication are thus operational in perpetuating the high viremic levels typical of the disease.…”
Section: Resultsmentioning
confidence: 61%
“…16 Cidofovir is the most potent inhibitor of KSHV productive infection. 18 Clinical and viral evidence presented here demonstrates that 4 months of therapy with cidofovir had no effect on KSHV-related MCD. Other mechanisms beyond productive viral replication are thus operational in perpetuating the high viremic levels typical of the disease.…”
Section: Resultsmentioning
confidence: 61%
“…34 Despite the apparently local growth of primary effusion lymphomas, our investigation demonstrates the early neoplastic spread to the bone marrow suggesting that the treatment of this peculiar lymphoma would be necessarily systemic. On the other hand, the role of multidrug resistance requires more extensive studies but its association with the proven toxicity of chemotherapy programs in immunocompromised patients, underlines the urgent need to explore different treatment modalities, such as the use of new antiviral drugs capable of inhibiting the virus replication 35 and new biological response modifiers.…”
Section: Discussionmentioning
confidence: 99%
“…Nucleoside analogs that selectively inhibit viral DNA replication are the first line anti-herpesvirus drugs. Originally developed to treat herpes simplex virus infection, they also inhibit KSHV in vitro 60,[64][65][66] and have displayed activity against KSHV-associated disease based on reductions in viral oropharyngeal shedding 67,68 and clinical relief of MCD symptoms. 34,35 At the outset, we considered three alternatives: (1) ganciclovir and the immunotoxin might display additive anti-KSHV activities; (2) they might detected on a small subpopulation of induced cells; this pattern was not observed on uninduced cells (data not shown).…”
Section: Resultsmentioning
confidence: 99%